Evidence map›Paper›PMID 37332327›Full record

ArticleOncology letters2023

Recurrence patterns are significantly associated with the

Wenju Liu, Xu Qiao, Hong Ge, Sheng Zhang, Xiaojiang Sun, Jiancheng Li, Weilin Chen, Wendong Gu, Shuanghu Yuan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. 2-[European journal of nuclear medicine and molecular imaging · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenju LiuDepartment of Radiation Oncology, Shandong University Cancer Center, Jinan, Shandong 250117, P.R. China.
Xu QiaoSchool of Control Science and Engineering, Shandong University, Jinan, Shandong 250117, P.R. China.
Hong GeDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, Henan 450000, P.R. China.
Sheng ZhangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.
Xiaojiang SunDepartment of Radiation Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China.
Jiancheng LiDepartment of Radiation Oncology, Fujian Cancer Hospital, College of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, Fujian 350000, P.R. China.
Weilin ChenDepartment of Radiation Oncology, Zhangzhou Hospital Affiliated to Fujian Medical University, Zhangzhou, Fujian 363000, P.R. China.
Wendong GuDepartment of Radiation Oncology, The Third Hospital Afiliated to Suzhou University, Changzhou, Jiangsu 213000, P.R. China.
Shuanghu YuanDepartment of Radiation Oncology, Shandong University Cancer Center, Jinan, Shandong 250117, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A model for predicting the recurrence pattern of patients with locally advanced non-small cell lung cancer (LA-NSCLC) treated with chemoradiotherapy is of great importance for precision treatment. The present study analyzed whether the comprehensive quantitative values (CVs) of the fluorine-18(

Indexed as

18F-FDG PET/CTchemoradiotherapylocally advanced non-small cell lung cancerrecurrence pattern

Identifiers

PMID37332327
PMCPMC10272971

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.